title: Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.
abstract: OBJECTIVE
  We aimed to evaluate the benefits of the glycoprotein (GP) IIb/IIIa antagonist, eptifibatide, after patients with acute coronary syndromes (ACS) were admitted to hospitals that approach revascularization for ACS through early transfer to tertiary referral centers.
  
  
  BACKGROUND
  Across a variety of hospital settings, GP IIb/IIIa inhibition, after patients were admitted to the hospital for non-ST segment elevation ACS, is associated with a reduction in death or myocardial infarction (MI) before and during a percutaneous coronary intervention.
  
  
  METHODS
  The outcomes of 429 patients from 153 sites in the Platelet glycoprotein IIb/IIIa in unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, who were transferred during study drug infusion ("transfer patients"), were compared with those of 1,987 patients who either remained in the hospital at those sites or were transferred after study drug termination ("nontransfer patients").
  
  
  RESULTS
  The baseline characteristics of transfer and nontransfer patients were similar. Patients receiving eptifibatide were transferred less frequently than those receiving placebo (16% vs. 20%, p = 0.014). Transfer patients underwent more procedures and experienced a greater 30-day incidence of death or MI, as compared with nontransfer patients (21% vs. 12%, p = 0.001). Eptifibatide was associated with a reduction in death or MI through 30 days, independent of transfer status (2.5% absolute reduction), as well as for those transferred (5.5% absolute reduction).
  
  
  CONCLUSIONS
  For patients with ACS admitted to community hospitals, eptifibatide is associated with a reduced need for transfer and improved clinical outcomes.
authors.affiliation: Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA. agreenb1@hfhs.org
authors.forename: A B
authors.initials: AB
authors.lastname: Greenbaum
authors.forename: R A
authors.initials: RA
authors.lastname: Harrington
authors.forename: M P
authors.initials: MP
authors.lastname: Hudson
authors.forename: C M
authors.initials: CM
authors.lastname: MacAulay
authors.forename: R G
authors.initials: RG
authors.lastname: Wilcox
authors.forename: M L
authors.initials: ML
authors.lastname: Simoons
authors.forename: L G
authors.initials: LG
authors.lastname: Berdan
authors.forename: A
authors.initials: A
authors.lastname: Guerci
authors.forename: D V
authors.initials: DV
authors.lastname: Cokkinos
authors.forename: M M
authors.initials: MM
authors.lastname: Kitt
authors.forename: A M
authors.initials: AM
authors.lastname: Lincoff
authors.forename: E J
authors.initials: EJ
authors.lastname: Topol
authors.forename: R M
authors.initials: RM
authors.lastname: Califf
authors.forename: E M
authors.initials: EM
authors.lastname: Ohman
mesh_terms: D000368:Aged; D003327:Coronary Disease / Q000188:drug therapy* / Q000401:mortality; D000077542:Eptifibatide; D005260:Female; D006764:Hospitals, Community; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D009204:Myocardial Revascularization; D010360:Patient Transfer; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012017:Referral and Consultation; D015996:Survival Rate
chemical_list: D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D000077542:Eptifibatide